Stockscreener 앱 받기
2.17
1.36%
-0.03
시간 외 거래:
2.35
0.18
+8.29%
전일 마감가:
$2.20
열려 있는:
$2.24
하루 거래량:
17,248
Relative Volume:
0.41
시가총액:
$1.35M
수익:
-
순이익/손실:
$-13.07M
주가수익비율:
-0.0533
EPS:
-40.717
순현금흐름:
$-16.23M
1주 성능:
-23.59%
1개월 성능:
-31.97%
6개월 성능:
-72.81%
1년 성능:
-95.25%
1일 변동 폭
$2.10
$2.31
1주일 범위
$2.0573
$2.7748
52주 변동 폭
$2.0573
$46.42
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
명칭
Cns Pharmaceuticals Inc
전화
1-800-946-9185
주소
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.17 | 1.36M | 0 | -13.07M | -16.23M | -40.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 개시 | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals shifts focus to neurology, oncology assets By Investing.com - Investing.com Nigeria
Quarterly Trades: Is CNS Pharmaceuticals Inc currently under institutional pressure2026 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail
CNS Pharmaceuticals shifts focus to neurology, oncology assets - Investing.com India
CNSP Implements New Strategy to Enhance Neurology and Oncology P - GuruFocus
CNS Pharmaceuticals Announces Strategic Shift to Neurology and Oncology Pipeline Expansion - citybuzz -
CNS Pharmaceuticals Launches Strategic Pivot Led by New Executive Team, Targeting High-Value Neurology and Oncology Assets for Investor Growth 123 - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion - Digital Journal
CNS Pharmaceuticals launches strategic pivot, names new executive team and begins asset search - TradingView
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline - ACCESS Newswire
New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan
CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan
Aug Final Week: Can CNS Pharmaceuticals Inc outperform under higher oil prices2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group - The Globe and Mail
Why is CNS Pharmaceuticals Inc stock going down2025 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
CNSP Earnings History & Surprises | EPS & Revenue Results | CNS PHARMACEUTICALS INC (NASDAQ:CNSP) - ChartMill
9,500 RSUs awarded to CNS Pharmaceuticals (CNSP) CFO - Stock Titan
CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan
CNSP Financials: Income Statement, Balance Sheet & Cash Flow | CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals (CNSP) awards CTO Eric Faulkner 9,500 RSUs - Stock Titan
CNS Pharmaceuticals Appoints New Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals names Lynne Kelley as chief medical officer By Investing.com - Investing.com Australia
CNS Pharmaceuticals (NASDAQ: CNSP) appoints new CMO Lynne Kelley - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team - Digital Journal
CNS Pharmaceuticals appoints Lynne Kelley as CMO - TipRanks
CNS Pharmaceuticals names Lynne Kelley as chief medical officer - Investing.com
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team - ACCESS Newswire
Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Price Action: Will CNS Pharmaceuticals Inc stock go up in YEARGDP Growth & Smart Investment Allocation Tips - baoquankhu1.vn
Breakout Watch: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. forming a bullish divergence2025 AllTime Highs & Expert Verified Movement Alerts - mfd.ru
Drug-Delivery Breakthroughs, Cross-Indication Research - GlobeNewswire
Chart Watch: How does CNS Pharmaceuticals Inc perform in inflationary periodsGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
CNS Pharmaceuticals appoints three new executives to leadership team - Investing.com South Africa
CNS Pharmaceuticals appoints three new executives to leadership team By Investing.com - Investing.com Canada
CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: Potential 41.67% Upside Amid Robust CNS Drug Portfolio - DirectorsTalk Interviews
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks
CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 - marketscreener.com
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Yahoo Finance
Levels Update: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. currently under institutional pressureFed Meeting & Free Long-Term Investment Growth Plans - mfd.ru
Is CNS Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Sector Review & Risk Managed Investment Strategies - mfd.ru
How CNS Pharmaceuticals Inc. stock performs in weak economy2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru
What are analysts’ price targets for CNS Pharmaceuticals Inc.July 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru
Why CNS Pharmaceuticals Inc. stock is recommended by analystsInsider Selling & Entry Point Strategy Guides - mfd.ru
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened - Defense World
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand - GlobeNewswire
Cns Pharmaceuticals Inc (CNSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):